Prevalence of Novel Candidate Sjogren Syndrome Autoantibodies in the Dry Eye Assessment and Management (DREAM) Study.
Prevalence of Novel Candidate Sjogren Syndrome Autoantibodies in the Dry Eye Assessment and Management (DREAM) Study.
复制标题
DOI：
10.1097/ico.0000000000001714
复制
发表时间：
2018-11
期刊：
影响因子：
2.8
通讯作者：
DREAM Study Research Group
中科院分区：
文献类型：
--
作者：
Bunya VY;Ying GS;Maguire MG;Kuklinski E;Lin MC;Peskin E;Asbell PA;DREAM Study Research Group
评估新型候选干燥综合征（SS）自身抗体（唾液蛋白-1（SP-1）、腮腺分泌蛋白（PSP）、碳酸酐酶6（CA-6））在干眼症评估和管理（DREAM©）队列中的患病率，该研究评估了omega-3脂肪酸补充剂治疗干眼症的有效性。参与者进行了眼表检查和传统和新型SS自身抗体的血清学检测。DREAM©参与者被分为以下3组：1）无SS或其他自身免疫性疾病病史和阴性传统SS自身抗体（n=352）; 2）无SS病史但有其他自身免疫性疾病病史（n=66）; 3）符合2012年美国风湿病学会SS分类标准（n=52）。11%有SS病史，6%没有SS病史的人最有可能患有未确诊的SS。SS组SP-1自身抗体的患病率高于无SS或其他自身免疫性疾病组（33% vs. 19%; p=0.02），但CA-6（p=0.31）或PSP自身抗体（p=0.33）无差异。仅传统自身抗体阳性或传统和新型自身抗体均阳性的参与者的角膜（p=0.002）和结膜染色（p<0.001）得分最高。这项多中心前瞻性研究的数据表明，一种新型候选自身抗体SP-1与潜在的SS相关，并且新型自身抗体可能与更严重的眼表疾病相关。未来的纵向研究需要评估其在筛查干眼患者SS中的效用。
To evaluate the prevalence of novel candidate Sjogren’s Syndrome (SS) autoantibodies (salivary protein-1 (SP-1), parotid secretory protein (PSP), carbonic anhydrase 6 (CA-6)), in the DRy Eye Assessment and Management (DREAM©) cohort, a study evaluating the effectiveness of omega-3 fatty acid supplements for the treatment of dry eye. Participants underwent ocular surface examinations and serological testing for traditional and novel SS autoantibodies. DREAM© participants were categorized into the following 3 groups: 1) no history of SS or other autoimmune disease and negative traditional SS autoantibodies (n=352); 2) no history of SS but a history of other autoimmune disease (n=66); and 3) those who met the 2012 American College of Rheumatology SS classification criteria (n=52). Eleven percent had a history of SS and 6% of those without a history of SS most likely had undiagnosed SS. The SS group had a higher prevalence of SP-1 autoantibodies than the group without SS or other autoimmune disease (33% vs. 19%; p=0.02), but had no difference in CA-6 (p=0.31) or PSP autoantibodies (p=0.33). Participants who were positive for the traditional autoantibodies alone, or positive for both traditional and novel autoantibodies had the highest scores for corneal (p=0.002) and conjunctival staining (p<0.001). Data from this multi-center, prospective study demonstrated that one of the novel candidate autoantibodies, SP-1, is associated with underlying SS and that novel autoantibodies may be associated with worse ocular surface disease. Future longitudinal studies are needed to evaluate their utility in screening dry eye patients for SS.